Heart failure drug reduction trial: could some patients take fewer pills?
NCT ID NCT07513883
First seen Apr 09, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This study looks at whether people whose heart failure has improved can safely cut back on their medications. Currently, patients are advised to take four drugs for life, but this can be costly and cause side effects. The trial will randomly assign 100 patients to either continue all medications or gradually reduce to just two drugs under close monitoring. Over two years, doctors will check heart function, blood tests, and track serious events like hospitalizations or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ziekenhuis Oost-Limburg
RECRUITINGGenk, 3600, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
down-titration of heart failure medications (SGLT2 inhibitor, mineralocorticoid receptor antagonist, and switching ARNI to ACE inhibitor or ARB)
What this could lead to
If successful, this could show that some heart failure patients in remission can safely take fewer medications, reducing side effects and costs.
What could go wrong
This is a small pilot study with only 100 participants. Reducing medications might cause heart function to worsen or lead to hospitalizations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.